Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y6M4

UPID:
KC1G3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9Y6M4; A8K040; B4DSH2; B7Z9Q4; E7EVD0; Q86WZ7; Q9Y6M3

BACKGROUND:
The protein Casein kinase I isoform gamma-3, with the unique identifier Q9Y6M4, functions as a serine/threonine-protein kinase. It is distinguished by its ability to utilize acidic proteins, such as caseins, for phosphorylation, affecting a multitude of proteins. Its participation in the Wnt signaling pathway and its regulatory role in glutamate-mediated fast synaptic transmission place it at a pivotal point in cellular signaling networks.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Casein kinase I isoform gamma-3 holds promise for unveiling novel therapeutic avenues. Given its pivotal role in Wnt signaling and synaptic transmission, targeting this kinase could lead to innovative treatments, particularly in diseases where these pathways are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.